Elevance Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Elevance Health (ELV).

Price Target Range — 8 Quarters

Analyst Consensus — 20 Analysts

14Buy

6Hold

Consensus RatingBuy# Analysts20Avg. Consensus PT$438Upside to Avg. PT+11.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 17, 2026	Bernstein	Lance Wilkes	PT Raise	Outperform	$482→$488
Jul 17, 2026	Leerink Partners	Whit Mayo	PT Raise	Market Perform	$364→$395
Jul 16, 2026	RBC Capital	Ben Hendrix	PT Cut	Sector Perform	$439→$424
Jul 16, 2026	Wells Fargo	Stephen Baxter	PT Cut	Overweight	$492→$473
Jul 16, 2026	Guggenheim	Jason Cassorla	PT Raise	Buy	$399→$455
Jul 16, 2026	Barclays	Andrew Mok	PT Cut	Overweight	$480→$457
Jul 16, 2026	Baird	Michael Ha	PT Raise	Neutral	$331→$393
Jul 14, 2026	TD Cowen	Ryan Langston	PT Raise	Buy	$400→$465
Jul 14, 2026	Truist Securities	David Macdonald	PT Raise	Buy	$450→$475
Jul 13, 2026	Wells Fargo	Stephen Baxter	PT Raise	Overweight	$391→$492
Jul 9, 2026	RBC Capital	Ben Hendrix	PT Raise	Sector Perform	$358→$439
Jul 7, 2026	Cantor Fitzgerald	Sarah James	PT Raise	Overweight	$400→$450
Jul 2, 2026	Bernstein	Lance Wilkes	PT Raise	Outperform	$424→$482
Jun 8, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$435→$465
Jun 8, 2026	JP Morgan	Lisa Gill	PT Raise	Overweight	$411→$476
Jun 4, 2026	B of A Securities	Kevin Fischbeck	PT Raise	Buy	$435→$460
Jun 4, 2026	Morgan Stanley	Erin Wright	PT Raise	Equal-Weight	$352→$404
Jun 1, 2026	Truist Securities	David Macdonald	PT Raise	Buy	$375→$450
May 26, 2026	Barclays	Andrew Mok	PT Raise	Overweight	$408→$480
May 22, 2026	UBS	A.J. Rice	PT Raise	Buy	$400→$460

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395

Leerink Partners analyst Whit Mayo maintains Elevance Health (NYSE:ELV) with a Market Perform and raises the price target from $364 to $395.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Lowers Price Target to $424

RBC Capital analyst Ben Hendrix maintains Elevance Health (NYSE:ELV) with a Sector Perform and lowers the price target from $439 to $424.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473

Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $492 to $473.

Benzinga Newsdesk

These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings

Elevance Health Inc. (NYSE:ELV) reported strong Q2 results and raised full-year guidance. Analysts have adjusted price targets for ELV stock.

Avi Kapoor

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455

Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $399 to $455.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $457

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $480 to $457.

Benzinga Newsdesk

Elevance Health Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Elevance Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Lowers Price Target to $424

PRO
Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473

These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455

PRO
Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $457

People Also Watch

People Also Watch

Elevance Health Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Elevance Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395

PRORBC Capital Maintains Sector Perform on Elevance Health, Lowers Price Target to $424

PROWells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473

These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings

PROGuggenheim Maintains Buy on Elevance Health, Raises Price Target to $455

PROBarclays Maintains Overweight on Elevance Health, Lowers Price Target to $457

People Also Watch

People Also Watch

PRO
Leerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Lowers Price Target to $424

PRO
Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455

PRO
Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $457